The Use of Biologics for Immune Modulation in Allergic Disease

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2019 Mar 19

PMID 30882368

Citations 28

Authors

Willem van de Veen

Mubeccel Akdis

Affiliations

Soon will be listed here.

Abstract

The rising prevalence of allergies represents an increasing socioeconomic burden. A detailed understanding of the immunological mechanisms that underlie the development of allergic disease, as well as the processes that drive immune tolerance to allergens, will be instrumental in designing therapeutic strategies to treat and prevent allergic disease. Improved characterization of individual patients through the use of specific biomarkers and improved definitions of disease endotypes are paving the way for the use of targeted therapeutic approaches for personalized treatment. Allergen-specific immunotherapy and biologic therapies that target key molecules driving the Th2 response are already used in the clinic, and a wave of novel drug candidates are under development. In-depth analysis of the cells and tissues of patients treated with such targeted interventions provides a wealth of information on the mechanisms that drive allergies and tolerance to allergens. Here, we aim to deliver an overview of the current state of specific inhibitors used in the treatment of allergy, with a particular focus on asthma and atopic dermatitis, and provide insights into the roles of these molecules in immunological mechanisms of allergic disease.

Citing Articles

Genetic background and microbiome drive susceptibility to epicutaneous sensitization and food allergy in adjuvant-free mouse model.

Hornikova T, Jelinkova A, Jiraskova Zakostelska Z, Thon T, Coufal S, Polouckova A Front Immunol. 2025; 15:1509691.

PMID: 39944558 PMC: 11814220. DOI: 10.3389/fimmu.2024.1509691.

Application of Nanoparticles for Immunotherapy of Allergic Rhinitis.

Li K, Jin J, Yang Y, Luo X, Wang Y, Xu A Int J Nanomedicine. 2024; 19:12015-12037.

PMID: 39583318 PMC: 11584337. DOI: 10.2147/IJN.S484327.

Dupilumab and House Dust Mite Immunotherapy in Patients with Atopic Dermatitis: A Preliminary Study.

Bogacz-Piaseczynska A, Bozek A, Krupka-Olek M, Kawczyk-Krupka A, Zalejska-Fiolka J, Canonica G Vaccines (Basel). 2024; 12(9).

PMID: 39340076 PMC: 11435717. DOI: 10.3390/vaccines12091046.

How type-2 dendritic cells induce Th2 differentiation: Instruction, repression, or fostering T cell-T cell communication?.

Ronchese F, Webb G, Ochiai S, Lamiable O, Brewerton M Allergy. 2024; 80(2):395-407.

PMID: 39324367 PMC: 11804308. DOI: 10.1111/all.16337.

Is Nasal Dysbiosis a Required Component for Neuroinflammation in Major Depressive Disorder?.

Vasquez-Perez J, Gonzalez-Guevara E, Gutierrez-Buenabad D, Martinez-Gopar P, Martinez-Lazcano J, Cardenas G Mol Neurobiol. 2024; 62(2):2459-2469.

PMID: 39120823 DOI: 10.1007/s12035-024-04375-2.

References

Borish L, Nelson H, Lanz M, Claussen L, Whitmore J, Agosti J . Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med. 1999; 160(6):1816-23. DOI: 10.1164/ajrccm.160.6.9808146. View

Stassen M, Arnold M, Hultner L, Muller C, Neudorfl C, Reineke T . Murine bone marrow-derived mast cells as potent producers of IL-9: costimulatory function of IL-10 and kit ligand in the presence of IL-1. J Immunol. 2000; 164(11):5549-55. DOI: 10.4049/jimmunol.164.11.5549. View

Gounni A, Nutku E, Koussih L, Aris F, Louahed J, Levitt R . IL-9 expression by human eosinophils: regulation by IL-1beta and TNF-alpha. J Allergy Clin Immunol. 2000; 106(3):460-6. DOI: 10.1067/mai.2000.109172. View

Abdelilah S, Latifa K, Esra N, Cameron L, Bouchaib L, Nicolaides N . Functional expression of IL-9 receptor by human neutrophils from asthmatic donors: role in IL-8 release. J Immunol. 2001; 166(4):2768-74. DOI: 10.4049/jimmunol.166.4.2768. View

Leckie M, Ten Brinke A, Khan J, Diamant Z, OConnor B, Walls C . Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2001; 356(9248):2144-8. DOI: 10.1016/s0140-6736(00)03496-6. View

Borish L, Nelson H, Corren J, Bensch G, Busse W, Whitmore J . Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol. 2001; 107(6):963-70. DOI: 10.1067/mai.2001.115624. View

Reche P, Soumelis V, Gorman D, Clifford T, Liu Mr , Travis M . Human thymic stromal lymphopoietin preferentially stimulates myeloid cells. J Immunol. 2001; 167(1):336-43. DOI: 10.4049/jimmunol.167.1.336. View

Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M . Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001; 108(2):E36. DOI: 10.1542/peds.108.2.e36. View

Busse W, Corren J, Lanier B, McAlary M, Fowler-Taylor A, Cioppa G . Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001; 108(2):184-90. DOI: 10.1067/mai.2001.117880. View

10.

Soler M, Matz J, Townley R, Buhl R, OBrien J, Fox H . The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001; 18(2):254-61. DOI: 10.1183/09031936.01.00092101. View

11.

Wilson D, Irani A, Walker S, Jacobson M, Mackay I, Schwartz L . Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy. 2001; 31(11):1705-13. DOI: 10.1046/j.1365-2222.2001.01231.x. View

12.

Soumelis V, Reche P, Kanzler H, Yuan W, Edward G, Homey B . Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002; 3(7):673-80. DOI: 10.1038/ni805. View

13.

Holgate S, Chuchalin A, Hebert J, Lotvall J, Persson G, Chung K . Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004; 34(4):632-8. DOI: 10.1111/j.1365-2222.2004.1916.x. View

14.

Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R . Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med. 2004; 199(11):1567-75. PMC: 2211782. DOI: 10.1084/jem.20032058. View

15.

Beck L, Marcotte G, MacGlashan D, Togias A, Saini S . Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol. 2004; 114(3):527-30. DOI: 10.1016/j.jaci.2004.06.032. View

16.

Gerber B, Pichler W . Cellular mechanisms of T cell mediated drug hypersensitivity. Curr Opin Immunol. 2004; 16(6):732-7. DOI: 10.1016/j.coi.2004.09.016. View

17.

Ying S, OConnor B, Ratoff J, Meng Q, Mallett K, Cousins D . Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J Immunol. 2005; 174(12):8183-90. DOI: 10.4049/jimmunol.174.12.8183. View

18.

Zhang K, Saxon A, Max E . Two unusual forms of human immunoglobulin E encoded by alternative RNA splicing of epsilon heavy chain membrane exons. J Exp Med. 1992; 176(1):233-43. PMC: 2119292. DOI: 10.1084/jem.176.1.233. View

19.

Zhou B, Comeau M, De Smedt T, Liggitt H, Dahl M, Lewis D . Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat Immunol. 2005; 6(10):1047-53. DOI: 10.1038/ni1247. View

20.

Ito T, Wang Y, Duramad O, Hori T, Delespesse G, Watanabe N . TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med. 2005; 202(9):1213-23. PMC: 2213234. DOI: 10.1084/jem.20051135. View